Cannabis-Like Drug's brain impact revealed in healthy volunteers

NCT ID NCT05885685

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at how nabilone, a cannabis-like drug, changes a brain enzyme called FAAH in 10 healthy adults. Participants took nabilone for one week and had brain scans before and after. The goal was to understand the drug's effect on brain chemistry, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

10 people

The number who actually took part.

Started

Oct 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 19-65 years old. For safety reasons, we will ask participants to provide photo ID showing birthdate, in order to verify age. * The ability to tolerate complete dosing regimen of nabilone (2mg titrated, 1 week course) * Able to sign and date informed consent form. * Willing and able to complete study as described in protocol Exclusion Criteria: * Serious, unstable medical condition including but not limited to cerebrovascular, renal, hepatic and coronary heart disease; * Coagulation/Blood Disorders or use of anticoagulant medication * Past or current neurological illness or head trauma; * Lifetime diagnosis of DSM-5 Axis I psychiatric conditions including mood, anxiety, eating, somatoform and/or psychotic disorders and substance abuse and/or dependence; * Suicidality or history of suicide attempts; * Family history of psychotic disorders (first degree relative with a psychotic disorder); * Current use (\~30 days) of drugs of abuse that may affect the CNS, including cannabis; * Tobacco dependence (Fagerstrom Test for Nicotine Dependence \>4); * Pregnancy or breastfeeding; * Presence of metal objects in the body or implanted electronic devices, that preclude safe MR scanning; * Claustrophobia; * Known sensitivity to marijuana or other cannabinoid agents; * Are on medications known to interact with nabilone such as: diazepam, sodium secobarbital, alcohol, codeine, any medications that affect mental and/or psychomotor function; * Positive during drug screening for drugs of abuse; * Exposure to radiation \<20 mSv in the last 12 months and a number of PET scans that, including the number of PET scans under this protocol, will bring the total to more than 8 PET scans/lifetime, exceeding permissible limit for subjects participating in research set by Brain Health Imaging Centre Guideline; * Participant has any other problem that, in the investigators opinion, would preclude participation in the trial;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    Toronto, Ontario, M5T 1R8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.